Suppression of hepatitis by DAA treatment may reduce inflammatory cytokines and preserve ASGPR function, thereby restoring the differentiation and proliferation potential of residual hepatocytes and improving the ability to synthesize albumin, prothrombin, and other substances. The gene discussed is ASGR1; the disease is Hepatitis.